| Summary: | Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes B cells that express CD20, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). It is available in 300 mg single-use vials for infusion. It is recommended that an initial 600 mg dose be administered as two separate intravenous (IV) infusions (initial 300 mg infusion followed by a second 300 mg infusion two weeks later), with subsequent ocrelizumab doses administered as single 600 mg IV infusions every six months. At the manufacturer's submitted unit price of $8,150 per 300 mg vial, ocrelizumab costs $32,600 per patient per year. The manufacturer's reimbursement request is per the Health Canada indication
|
|---|